Key points of post-marketing evaluation of classic traditional Chinese medicine prescriptions based on combination of disease and syndrome.
10.19540/j.cnki.cjcmm.20210213.502
- Author:
Xin-Lu WANG
1
;
Ming-Jun ZHU
1
;
Jian-Ru WANG
1
;
Bin LI
1
;
Rui YU
1
;
Guang-Cao PENG
1
;
Qi-Fei ZHAO
1
;
Yong-Xia WANG
1
Author Information
1. the First Affiliated Hospital of Henan University of Chinese Medicine Zhengzhou 450000, China.
- Publication Type:Journal Article
- Keywords:
classic traditional Chinese medicine prescriptions;
combination of disease and syndrome;
post-marketing evaluation
- MeSH:
Drugs, Chinese Herbal/therapeutic use*;
Humans;
Marketing;
Medicine, Chinese Traditional;
Prescriptions;
Reference Standards
- From:
China Journal of Chinese Materia Medica
2021;46(8):2004-2009
- CountryChina
- Language:Chinese
-
Abstract:
Classic prescriptions, hospital preparations and famous traditional Chinese medicine(TCM) experience prescriptions are the main sources of new drug development and innovation. The multi-components and multi-targets treatment characteristics of TCM are advantages, but at the same time, broad indications, unclear clinical positioning and lack of evidence-based evidence support are the key problems affecting the play of TCM efficacy and restricting its promotion and application. The hot in recent research was to how to break through the bottleneck, precise clinical positioning, highlight the advantages of the classic TCM prescriptions, and complete the transformation from clinical practice, clinical research to clinical evidence, but at the same time, it is also the difficulty. The clinical research model of the combination of disease and syndrome can fully reflect the ancient medical case evidence of classic TCM prescriptions, the historical experience of human used and the characteristics of syndrome differentiation and treatment, and highlight the advantages of Chinese medicine. At the same time, under the modern disease classification system and research mode, is conducive to established the standardized clinical evidence report and evaluation system, is conducive to promote the integration of clinical research evidence, and avoids excessive attenuation of information. Based on the previous work of our team, the intention of this study was to make a comment about the key points of the post-marketing evaluation of the classic TCM prescriptions under the combination of disease and syndrome and includes key points:(1)With the syndrome as the carrier, connected with the classical prescription and clinical diseases, focused on the clinical positioning on macroscopically.(2)The combination of syndrome visualization, standardization and pharmacological molecular basis, focus on clinical precise positioning in microscopic.(3)Innovating therapeutic effect evaluation methods, reflecting the curative effect characteristics based on syndrome differentiation.(4)The combination of "randomized controlled evidence-based studies" and "real world evidence-based evaluation", focusing on clinical advantages, fully evidence-based evidence.(5)Make full use of clinical registration studies and pay attention to safety.
